Show simple item record

Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting

hal.structure.identifierMount Sinai Medical Center
hal.structure.identifierCardiovascular Research Foundation
dc.contributor.authorMehran, Roxana
hal.structure.identifierMount Sinai Medical Center
dc.contributor.authorVogel, Birgit
hal.structure.identifierLaboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
dc.contributor.authorLévy, Pierre
HAL ID: 10931
dc.date.accessioned2021-01-25T14:57:07Z
dc.date.available2021-01-25T14:57:07Z
dc.date.issued2021
dc.identifier.issn0914-5087
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/21543
dc.language.isoenen
dc.subjectAtrial fibrillationen
dc.subjectCosten
dc.subjectPercutaneous coronary interventionen
dc.subjectBleeding complicationsen
dc.subjectThrombosisen
dc.subject.ddc334en
dc.subject.classificationjelI.I1.I18en
dc.subject.classificationjelI.I1.I12en
dc.titleReducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stentingen
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenPatients undergoing percutaneous coronary intervention (PCI) have an increased risk of both ischemic events and bleeding complications resulting from antithrombotic therapy. These events are particularly common in patients with a concomitant indication for oral anticoagulation, such as those with atrial fibrillation, and are associated with a substantial healthcare resource burden. Advances in procedural aspects of PCI have led to marked improvements in outcomes and a consequent reduction in the costs resulting from PCI-associated complications. Furthermore, recent randomized clinical trials have investigated the optimal antithrombotic strategy in the specific case of patients with atrial fibrillation undergoing PCI, leading to a shift toward the tailoring of antithrombotic therapy according to the patient’s individual stroke and bleeding risks. Here we review these recent advances, with a particular focus on the improvements in antithrombotic strategies offered by the non-vitamin K antagonist oral anticoagulantsen
dc.relation.isversionofjnlnamejournal of Cardiology
dc.relation.isversionofjnlvol77en
dc.relation.isversionofjnlissue1en
dc.relation.isversionofjnldate2021
dc.relation.isversionofjnlpages93-99en
dc.relation.isversionofdoi10.1016/j.jjcc.2020.07.018en
dc.relation.isversionofjnlpublisherElsevieren
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
dc.description.ssrncandidatenonen
dc.description.halcandidateouien
dc.description.readershiprechercheen
dc.description.audienceInternationalen
dc.relation.Isversionofjnlpeerreviewedouien
dc.relation.Isversionofjnlpeerreviewedouien
dc.date.updated2021-01-25T14:23:22Z
hal.identifierhal-03120565*
hal.version1*
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record